Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 4/20 | 0.68 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
| ▸ | REN | P00797 | 1/20 | 0.60 |
| ▸ | CTSS | P25774 | 4/20 | 0.59 |
| ▸ | CTSK | P43235 | 3/20 | 0.59 |
| ▸ | CTSL | P07711 | 1/20 | 0.59 |
| ▸ | CTSB | P07858 | 1/20 | 0.59 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.58 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.57 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.57 |
| ▸ | MMP9 | P14780 | 1/20 | 0.56 |
| ▸ | MMP8 | P22894 | 1/20 | 0.56 |
| ▸ | PSMB10 | P40306 | 4/20 | 0.55 |
| ▸ | PSMB1 | P20618 | 3/20 | 0.55 |
| ▸ | PSMB9 | P28065 | 3/20 | 0.55 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.55 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.55 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.55 |
| ▸ | MME | P08473 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5833552 | 1.00 | BCL2 (0.68) | BCL2PTPN1HDAC8RENCTSS | |
| SCHEMBL5833941 | 0.92 | BCL2 (0.60) | BCL2PTPN1HDAC8RENCTSS | |
| SCHEMBL7283537 | 0.90 | MMP9 (0.69) | BCL2PTPN1HDAC8RENCTSS | |
| SCHEMBL7283532 | 0.90 | MMP9 (0.69) | BCL2PTPN1HDAC8RENCTSS | |
| SCHEMBL7348417 | 0.90 | CTSS (0.71) | HDAC8RENCTSSCTSKCTSL | |
| SCHEMBL7348426 | 0.90 | CTSS (0.71) | HDAC8RENCTSSCTSKCTSL | |
| SCHEMBL193473 | 0.89 | PTPN1 (0.73) | BCL2PTPN1HDAC8CTSSCTSK | |
| SCHEMBL193474 | 0.89 | PTPN1 (0.73) | BCL2PTPN1HDAC8CTSSCTSK | |
| SCHEMBL2891538 | 0.89 | PTPN1 (0.73) | BCL2PTPN1HDAC8CTSSCTSK | |
| SCHEMBL7337738 | 0.88 | CTSS (0.65) | HDAC8RENCTSSCTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989448-B2 | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers | HU LAIN-YEN | 2006-01-24 | — | — | US | disclosed |
| US-20030060419-A1 | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers | HU LAIN-YEN (US) | 2003-03-27 | — | — | US | disclosed |
| US-6469038-B1 | CALCIUM CHANNEL BLOCKERS THAT CAN BLOCK N-TYPE CALCIUM CHANNELS AND CAN BE USED TO TREAT STROKE, PAIN, CEREBRAL ISCHEMIA, HEAD TRAUMA, ASTHMA, AMYOTROPIC LATERAL SCLEROSIS, AND EPILEPSY | WARNER-LAMBERT COMPANY | 2002-10-22 | — | — | US | disclosed |
| US-6423689-B1 | Peptidyl calcium channel blockers | WARNER-LAMBERT COMPANY | 2002-07-23 | — | — | US | disclosed |
| US-6362174-B1 | ANALGESICS, ANTIISCHEMIC AGENTS, ANTIEOILEPTIC AGENTS | WARNER-LAMBERT COMPANY | 2002-03-26 | — | — | US | disclosed |
| US-20020028801-A1 | Reduced dipeptide analogues as calcium channel antagonitsts | RAFFERTY MICHAEL FRANCIS (US) | 2002-03-07 | — | — | US | disclosed |
| US-6323243-B1 | AROMATIC ETHER WITH AMINE OR AMIDE GROUPS | WARNER-LAMBERT COMPANY | 2001-11-27 | — | — | US | disclosed |
| US-6316440-B1 | TREATMENT OF STROKE, HEAD TRAUMA, CEREBRAL ISCHEMIA, PAIN AND EPILEPSY | WARNER-LAMBERT COMPANY | 2001-11-13 | — | — | US | disclosed |
| US-6180677-B1 | ANTIEPILEPSY AGENT | WARNER-LAMBERT COMPANY | 2001-01-30 | — | — | US | disclosed |
| US-6166052-A | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers | WARNER-LAMBERT COMPANY (US) | 2000-12-26 | — | — | US | disclosed |
| US-6117841-A | USED TO TREAT STROKE, CEREBRAL ISCHEMIA, PAIN, HEAD TRAUMA OR EPILEPSY | WARNER-LAMBERT COMPANY (US) | 2000-09-12 | — | — | US | disclosed |
| WO-2000006535-A1 | TYROSINE-DERIVED COMPOUNDS AS CALCIUM CHANNEL ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060419-A1 | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers | CACNA1C, CACNA1I, CACNA1S | BCL2 1044/4885PTPN1 4174/4885HDAC8 3222/4885 |
| US-20020028801-A1 | Reduced dipeptide analogues as calcium channel antagonitsts | CACNA1E, RYR1, CACNA1B | BCL2 1790/4885PTPN1 1997/4885HDAC8 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.